Introduction
============

Effective and widespread cervical cancer screening has greatly reduced cervical cancer incidence and related morbidity and mortality[@R1]. The most commonly used cervical cancer screening method worldwide is a Pap test, which involves the collection of cervical cells for examination under a microscope by a cytopathologist. Pap testing detects abnormal cells in the cervix and enables early detection and treatment of cervical cancer[@R1]. However, Pap screening programs have low feasibility in limited-resource settings owing to a lack of infrastructure and trained personnel, limited health budgets and competing healthcare priorities[@R2],[@R3]. To address these barriers, some national screening programs use alternatives to traditional cytology (Pap testing), such as visual inspection of the cervix with acetic acid (VIA). VIA involves unaided (naked eye) inspection of the cervix after application of acetic acid to identify abnormal tissue. While VIA eliminates some constraints of Pap testing, such as cost and need for multiple visits, there can be high variability by provider in the quality of VIA screening[@R4]--[@R6].

DNA testing for human papillomavirus (HPV) offers an accurate alternative to VIA. The WHO recommends hr-HPV DNA testing as the primary cervical cancer screening approach in places where Pap testing has not been established[@R7]. Similar to other screening methods, cervical samples are typically gathered by a clinician during the course of a pelvic examination, but samples can also be self-collected by women themselves with a swab. WHO recommends screening with an HPV test and treatment over screening with VIA and treatment where feasible[@R7]. HPV testing is also recommended as first line screening followed by VIA and treatment[@R7].

When successfully introduced, self-collection of samples for HPV testing can increase screening for hard to reach women or women who do not come in for screening tests[@R8]--[@R11]. Self-collected samples have been shown to perform comparably to clinician-collected samples, but published findings suggest that the population and method of collection or testing are important to consider when assessing the utility of self-collected samples[@R12]--[@R15].

The recently lowered costs of HPV DNA testing may make this method of cervical cancer screening a viable screening option in a wide variety of settings. Combined with evidence that self-collection is a more effective way to screen women[@R16]--[@R19], we aimed to evaluate how this method of sample collection performed in a low-resource setting. Previous research suggests that many women in rural Malawi would be willing to self-collect a sample at home, yet no research has examined self-collection in a clinical setting or whether women\'s hypothetical willingness would translate into actual behavior if offered an opportunity to provide a self-collected sample. We sought to assess the validity, feasibility and acceptability of using the GeneXpert HPV Assay to test self-collected vaginal samples in a rural clinic in Lilongwe District, Malawi.

Methods
=======

Study setting and population
----------------------------

Women were recruited for this study as part of a larger, clinic-based study examining sexual and reproductive tract infections. Briefly, from January to August 2015, any woman who presented to the study clinic in rural Lilongwe District, Malawi, with any genitourinary symptom (including abnormal menstrual cycle or patterns of bleeding; pain with urination, pain during sex, abdominal pain, lower back pain, or any type of pelvic pain; incontinence or unusual urine odour, frequency or colour; unusual vaginal discharge in terms of quantity, odour, colour or consistency) was referred to study staff to be assessed for eligibility. Women were eligible to participate if they were 18--49 years of age, spoke *Chichewa*, had at least one genitourinary symptom, consented to be examined and give biological specimens for testing, and resided in Lilongwe District. Women who were pregnant or menstruating were ineligible. Women provided written informed consent to participate either by signature or thumbprint.

Data collection
---------------

### Screening

Women were examined in a private clinic room by the study clinician. At the start of the exam, each woman was offered the option to self-collect a vaginal sample for HPV testing. If she agreed, she was given a sterile, cotton-tipped swab and instructions on how to collect the vaginal sample. The clinician remained in the study room, on the other side of a privacy screen, in case the participant had any questions about collecting the sample. After collection, the clinician placed the swab in 20 ml of Preservcyt solution (Hologic, Bedford, Massachusetts) and proceeded to perform a pelvic examination. The clinician used an endocervical brush to collect the sample for HPV testing. Following collection, he swirled the cervical brush in 20 ml of Preservcyt solution. Both clinician- and self-collected samples were stored between 2 and 8°C and were tested using the GeneXpert HPV assay at the end of the study (Cepheid, Sunnyvale, California).

The GeneXpert technology was developed to identify multi-drug resistant tuberculosis, and WHO supported the roll-out of GeneXpert systems for tuberculosis control programs in 21 countries throughout Africa and Asia[@R15]. While HPV testing using the GeneXpert is a new application of this technology, the GeneXpert platform is ubiquitous throughout Africa, including Malawi, and its use is supported by the Malawi Ministry of Health. The GeneXpert HPV test yields results in four categories: (a) negative for hr-HPV; (b) positive for HPV[@R16]; (c) positive for HPV[@R18] or 45; or (d) positive for one of 11 pooled hr-HPV types (31, 33, 35, 39, 51, 52, 56, 58, 59, 66, and 68; [Figure 1](#F1){ref-type="fig"}). The GeneXpert also includes quality assurance channels for sample adequacy control and a probe check control.

![Potential outcomes of GeneXpert HPV assay](MMJ3002-0061Fig1){#F1}

All results from the HPV testing were recorded on paper forms and entered into an electronic spreadsheet by trained research staff.

#### Questionnaire

After the clinical exam, the patient was sent to a separate study room where a research assistant, who did not provide clinical care, administered a brief questionnaire capturing demographic characteristics and the acceptability of the self-collection procedure. The questionnaire included items about the ease of collecting samples and understanding instructions, using a 5-point scale ranging from very easy to very difficult. Using the same scale, we also assessed women\'s confidence in their ability to self-collect a sample, their preferences for collection of samples for HPV testing, whether they would recommend self-collection to a friend, and concerns about self-collection. Questions were developed based on previous literature and work of the study authors. All survey questions were recorded directly into the Magpi data collection system (Magpi, Washington, DC) and uploaded to an internet-based storage system daily.

Testing of clinician- and self-collected samples was not completed until the end of the research study; therefore, we did not inform women if they had hr-HPV. However, women found to have hr-HPV were referred to VIA, and all participants in the research study underwent VIA as part of the research protocol. Treatment for abnormal lesions was not available at the study clinic, and thus women with abnormal VIA results were referred to secondary care at one of two district hospitals in Lilongwe. The referral appointments were scheduled within a week of the study visit, and participants were provided with funds to facilitate travel to and from Lilongwe. Study clinicians requested records documenting care received at the district hospitals.

### Data analysis

We first described the prevalence of hr-HPV in the study population, overall and by the four separate GeneXpert result categories for both self- and clinician-collected samples. We then calculated the sensitivity and specificity of self-collected samples, using the clinician-collected samples as a reference standard. In order to assess agreement between the two sampling methods, we calculated a kappa statistic for overall hr-HPV type (positive for any hr-HPV vs. hr-HPV-negative) and by the 3 GeneXpert hr-HPV categories (HPV 16, HPV 18/45, additional hr-HPV types). As HPV testing is recommended only in women over 30 years of age due to the transient nature of HPV infections in younger women, we also conducted analyses restricting our sample to women over 30 years (n=126). Finally, using questionnaire data, we calculated frequencies to describe acceptability of self-collection among participants. All analyses were done using Stata 14.0 (StataCorp, College Station, TX).

### Ethical approval

This project received ethical approval from the Ohio State University Institutional Review Board and the University of Malawi College of Medicine Research and Ethics Committee.

Results
-------

### Study population and prevalence of hr-HPV infections with clinician-collected sampling

We screened 234 women to enroll 200 in the parent study, 199 of whom consented to HPV testing. Women without hr-HPV were slightly older than women with any hr-HPV (median age 34 vs. 32 years) and more likely to be married (97% vs. 77%; [Table 1](#T1){ref-type="table"}). Sixteen women (8%) were initially noted as having a positive VIA screen although two of these were later determined to be false positives. Of the remaining 14 women, 10 presented with acetowhite lesions and four with inconclusive results that required additional screening. All 14 women were referred to the district hospital for additional screening and treatment as services were not available in the study clinic.

###### 

Participant characteristics of 199 care-seeking women by clinician-collected HPV results

  ---------------------------------------------------------------------------------
                                  Any hr-HPV[@R1]   No hr-HPV            
  ------------------------------- ----------------- ----------- -------- ----------
  Education                                                              

  \< 2 years                      4                 \(9\)       17       \(11\)

  2--4 years                      10                \(23\)      20       \(13\)

  5--8 years                      16                \(37\)      66       \(42\)

  \>8 years                       13                \(30\)      53       \(34\)

  Marital status                                                         

  Married                         33                \(77\)      151      \(97\)

  Single                          10                \(23\)      5        \(2\)

  Condom use last sex                                                    

  Yes                             5                 \(23\)      13       \(14\)

  No                              17                \(77\)      77       \(86\)

  Ever heard of cervical cancer                                          

  Yes                             36                \(86\)      151      \(97\)

  No                              6                 \(14\)      4        \(3\)

  Abnormal VIA                                                           

  Yes                             4                 \(9\)       10       \(6\)

  No                              39                \(91\)      145      \(94\)

                                                                         

                                  Median            (IQR)       Median   (IQR)

                                                                         

  Age                             32                (27, 36)    34       (29, 39)

  Lifetime number of sexual\      2                 (2,3)       2        (1,2)
  partners                                                               
  ---------------------------------------------------------------------------------

Among the women tested for HPV, 22% (n=43) had any type of hr-HPV by clinician-collected sample ([Table 2](#T2){ref-type="table"}). Six women were infected with multiple HPV types: one woman tested positive for HPV 16, HPV 18/45, and additional hr-HPV type(s), 4 women had both HPV 18/45 and additional hr-HPV type(s), and one woman had HPV 16 and additional hr-HPV type(s).

###### 

HPV results, by collection modality

                                       Clinician   Self           
  ------------------------------------ ----------- -------- ----- --------
                                       n           (%)      n     (%)
                                                                  
  None[1](#TF1){ref-type="table-fn"}   156         \(78\)   166   \(83\)
  Any hr-HPV                           43          \(22\)   33    \(17\)
  HPV 16                               8           \(4\)    4     \(2\)
  HPV 18/45                            11          \(6\)    11    \(6\)
  Additional hr-HPV                    23          \(15\)   24    \(12\)

HPV results grouped by GeneXpert category.

### Agreement between clinician-collected and self-collected samples

We found high agreement between HPV results from self- and clinician-collected samples as measured by the kappa statistic, which measures agreement beyond chance alone. The highest agreement between self- and clinician-collected samples was for HPV 18/45 (ϰ = 0. 90). The agreement between self- and clinician-collected samples for any type of hr-HPV and the additional hr-HPV types were similar (ϰ=0.77, ϰ=0.74; Table 3). Overall compared to clinician-collected samples, self-collected samples were highly specific and varied in sensitivity by type of HPV (Table 3). Whereas specificity was 98-100% depending on hr-HPV type, sensitivity was poorer; we found the highest sensitivity for HPV 18/45 at 91% (95% CI: 59%, 100%) and lowest sensitivity for HPV 16 at 50% (95% CI: 16%, 84%).

When restricting the analyses to women older than 30 years, based on current HPV testing guidelines, we found that there was increased sensitivity for detection of all hr-HPV types combined, HPV 16 and additional hr-HPV, but a decrease in sensitivity for detection of HPV 18/45 ([Table 4](#T4){ref-type="table"}). The exclusion of younger women also led to an increase in most kappa values characterizing agreement between clinician and self-collected samples, including for all categories of hr-HPV (ϰ = 0.83), HPV 16 (ϰ=0.85) and the additional hr-HPV category (ϰ=0.77). Restricting to older women (who are likely to have fewer transient infections) we found that in general there was increased kappa agreement and sensitivity although it was not consistent across all hr-HPV types.

###### 

Concordance between HPV test results by self- and clinician-collected samples in women older than 30 years of age

                        Sensitivity   (95% CI)    Specificity   (95% CI)    Kappa[1](#TF2){ref-type="table-fn"}   (95% CI)
  --------------------- ------------- ----------- ------------- ----------- ------------------------------------- --------------
  All types of hr-HPV   79            (57, 93)    99            (95, 100)   0.83                                  (0.71, 0.96)
  HPV 16                75            (19, 99)    100           (97, 100)   0.85                                  (0.57,1.0)
  HPV 18/45             83            (36, 100)   99            (95, 100)   0.82                                  (0.59,1.0)
  Other hr-HPV          75            (48, 93)    98            (94, 100)   0.77                                  (0.60,0.95)

Kappa measures expected vs. observed agreement

### Acceptability

Overall, women found the self-collection procedure easy to perform (98%), reported that the instructions were easy to understand (100%), and were confident they did it correctly (95%; [Table 5](#T5){ref-type="table"}). Most women reported they would recommend self-collection for HPV testing to a friend (99%) and more women preferred self-collection compared to clinician-collection sampling (61% vs. 39%).

###### 

Acceptability of self-collection[1](#TF3){ref-type="table-fn"}

                                                                         n     (%)
  ---------------------------------------------------------------------- ----- ---------
  Very or somewhat easy to understand the self-collection instructions   197   \(100\)
  Recommend self-collection to a friend                                  193   \(99\)
  Very or somewhat easy to do self-collcctLon of samples                 194   \(98\)
  Would use self-collection for HPV testing in the future                194   \(99\)
  Very or somewhat certain self-collected correctly                      186   \(95\)
  Prefer self-collection over clinician-collection                       119   \(61\)
                                                                               
  Concerns about self-collection                                               
                                                                               
  No concerns                                                            138   \(74\)
  Might hurt                                                             22    \(12\)
  Might not be accurate                                                  20    \(11\)
  Might not do it correctly                                              14    \(7\)

Women could select multiple concerns

Three-quarters of women (74%) reported they would not have any concerns about self-collecting for HPV testing in the future. Among those who expressed concerns, 12% reported worries that self-swabbing might hurt, 11% feared the HPV results following self-collection might not be accurate, and 7% were concerned they may not test correctly.

Discussion
----------

To our knowledge, this is the first study to examine self-collected samples for HPV testing using the GeneXpert HPV assay in a low resource setting. Our findings suggest that self-collection of samples for HPV testing is a feasible and acceptable method of cervical cancer screening in this rural, Malawian population. While the specificity was high, we found lower levels of sensitivity suggesting that self-collected samples for HPV testing may not be as valid as clinician-collected samples. The self-collection procedure was easy to incorporate into the clinic setting with all but one participant providing a sample, and all collected samples were sufficient for testing. High agreement between the self- and clinician-collected samples, and high levels of acceptability among participants, suggest that self-collection procedures for HPV testing may be effectively incorporated into screening programs among rural, largely unscreened populations in Malawi.

Using a new HPV DNA test, we found lower sensitivity but high agreement in HPV test results between self- and clinician-collected samples, in line with previous research on other tests from a range of settings (kappa values ranging from 0.70--0.87)[@R20]--[@R24]. Our findings also align with previous research that suggests agreement in HPV results from self-and clinician-collected samples can vary by HPV type[@R21]. While the specificity of the self-collected tests was very high in our study, sensitivity varied by type of HPV. In other words, HPV testing using self-collected samples accurately detected HPV-negative women, but the ability to detect HPV-positive women using self-collected samples was more variable. When younger women were excluded from the sample, sensitivity was more comparable across the different types of hr-HPV, although the sensitivity for detection of HPV 18/45 was slightly reduced. This overall pattern of lower sensitivity but higher specificity of self-collected vs. clinician-collected samples is similar to findings from a study of Gambian women, where self-collected samples had a sensitivity of 0.64 (95% CI: 0.52, 0.83) and specificity of 0.94 compared to clinician-collected cervical samples[@R25].

Our findings suggest that self-collection of samples for HPV testing was widely acceptable, easy to perform and preferred to clinician-collection. Combined with results from other research, our study provides evidence that self-collection could be used in an outreach capacity to increase screening in hard-to-reach populations. For example, among women in Argentina, women who were offered the opportunity to self-collect a sample in the home through community health workers were four times as likely to be screened for cervical cancer than women who were not offered the option to self-collect[@R15]. In a randomized control trial conducted in Uganda, 98% of women in the HPV self-collection arm were screened for cervical cancer while in the control arm (VIA), only 48% of women received cervical cancer screening[@R26].

To be successfully implemented, screening programs using HPV testing will need to consider clinician and laboratory perspectives alongside other programmatic considerations. For example, in our project, the study clinician found that after a small number of participants had enrolled, it was very simple to collect cervical samples using the cervical brush. On the other hand, he experienced challenges explaining the self-collection procedure to women, suggesting that a future screening program must provide detailed instructions or have present a healthcare provider to answer questions. The laboratory technician found it easy and fast to test samples using the GeneXpert HPV test. However, some samples required a repeat test due to machine error and added to costs of HPV testing. We also experienced challenges in procuring the transport medium - an expensive part of the testing procedure, and this supply issue must be addressed before a larger rollout of any HPV testing program is possible in this region. Studies of other polymerase chain reaction (PCR)-based HPV DNA tests suggest that more commercially-available and inexpensive transport media (e.g. Scope mouthwash[@R27]) or the collection and storage of dry samples, may perform comparably[@R27],[@R28], although to date these approaches have not been validated for the GeneXpert HPV DNA test.

Our findings must be interpreted in light of important study limitations. As our project was undertaken as a secondary arm of a larger study, the population included younger women (under age 30) for whom HPV testing is not currently recommended. However, subgroup analyses with older women in the recommended range suggest that kappa of self- and clinician-collected samples and sensitivity and specificity findings were valid for both groups. As this project was nested in a pilot study, we had a relatively small sample size, especially when excluding women under age 30. The smaller sample size may have influenced the lower sensitivity for self-collected samples. Generalizability of our results may also be limited as we enrolled care-seeking women who presented with genitourinary symptoms to a medical facility. As HPV infections and early cervical lesions do not lead to noticeable symptoms, it will be important to determine whether HPV screening (via self-collected samples) remains acceptable in women without genitourinary symptoms. We also enrolled women presenting at a clinic, so we cannot extrapolate our results to cervical cancer screening programs in an outreach capacity. Additionally, our study clinician was in the room during self-collection of the sample which may not be generalizable to an outreach setting where there are not trained personnel available. Our study also only assessed the feasibility of self-collection compared to clinician-collected sampling, but we note that WHO guidelines recommend immediate treatment be available for any clinic-based cervical cancer screening program. Lastly, the acceptability questions may be influenced by response bias with participants voicing more favorable views on self-collection than they actually felt. We attempted to minimize this bias by having a non-clinician research assistant deliver the questions in a separate, study room.

While the rates of cervical cancer incidence and mortality have decreased precipitously in the last 40 years globally, the burden of disease falls disproportionally on women in low-resource settings without accessible screening programs. Although we have demonstrated some of the utility of screening, Malawians remain with significant challenges in providing appropriate therapy in a reliable and sustainable way. While we did not deal with the whole scope of necessary care, we did assess one part of the pathway, and demonstrated that it could be useful in the arc of care that women need.

Conclusion
==========

Self-collecting samples for HPV testing has the potential to eliminate many of the barriers of other cervical cancer screening programs that restrict access for women in low-resource settings. We submit that cervical cancer-screening programs using self-collected samples for HPV testing may be a feasible, valid, acceptable, and effective cervical cancer screening method in this rural Malawian population.
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